| First Author | Hinrichs CS | Year | 2009 |
| Journal | Blood | Volume | 114 |
| Issue | 3 | Pages | 596-9 |
| PubMed ID | 19471017 | Mgi Jnum | J:150734 |
| Mgi Id | MGI:3851642 | Doi | 10.1182/blood-2009-02-203935 |
| Citation | Hinrichs CS, et al. (2009) Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114(3):596-9 |
| abstractText | Interleukin-17 (IL-17)-secreting CD8(+) T cells have been described, but they have not been thoroughly studied and they do not have a known role in cancer immunotherapy. We skewed CD8(+) T cells to secrete IL-17 through priming in Th17-polarizing conditions. IL-17-producing CD8(+) T cells demonstrated reduced expression of Eomes and diminished cytolytic differentiation in vitro. However, after adoptive transfer, these cells converted to interferon-gamma-producing effector cells and mediated regression of large, established tumors. This improved antitumor immunity was associated with increased expression of IL-7R-alpha, decreased expression of killer cell lectin-like receptor G1, and enhanced persistence of the transferred cells. This report is the first description of a cancer therapy with IL-17-secreting CD8(+) T cells. These findings have implications for the improvement of CD8(+) T cell-based adoptive immunotherapy. |
